Filing Flows

Filing Flows › Companies › Metagenomi Therapeutics › Cash flow

Metagenomi Therapeutics cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$19.6M in Q2 2026 · −$85.8M over twelve months

Operating cash flow−$19.5M
Capital spending−$125K
Free cash flow−$19.6M

Analysis

In Q2 2026, Metagenomi Therapeutics generated −$19.5M of operating cash flow and spent $125K on capital projects, leaving free cash flow of −$19.6M. That is $1.7M more than in Q2 2025 (−$21.4M).

Over the twelve months to Jun 30, 2026, operating cash flow was −$85.5M; the largest uses were operating cash flow ($85.5M), capital spending ($309K), other financing ($73K); besides operations, cash came from other investing ($97.2M); the cash balance rose by $11.3M.

Operating cash flow was −$19.5M against net income of −$27.5M. The largest differences: accrued liabilities +$2.9M, stock-based pay +$2.3M, depreciation & amortization +$1.3M.

Free cash flow

Metagenomi Therapeutics: free cash flow by quarterMetagenomi Therapeutics: free cash flow by quarter−$27.8MQ3 2024−$26.6MQ4 2024−$23.1MQ1 2025−$21.4MQ2 2025−$21.3MQ3 2025−$23.6MQ4 2025−$21.2MQ1 2026−$19.6MQ2 2026
Operating cash flow less capital spending.
Metagenomi Therapeutics: operating cash flow against capital spendingMetagenomi Therapeutics: operating cash flow against capital spendingOperating cash flowCapital spending−$26.6M$1.2MQ3 2024−$26.3M$334KQ4 2024−$22.8M$288KQ1 2025−$21.3M$127KQ2 2025−$21.3M$74KQ3 2025−$23.5M$85KQ4 2025−$21.2M$25KQ1 2026−$19.5M$125KQ2 2026
Latest (Q2 2026): Operating cash flow −$19.5M, Capital spending $125K.

Capital allocation, year by year

Metagenomi Therapeutics: where the cash came from (up) and went (down), by fiscal yearMetagenomi Therapeutics: where the cash came from (up) and went (down), by fiscal yearOperating cash flowShares issuedAsset salesCapital spendingFY2023: Operating cash flow −$91.4MFY2023: Shares issued $4.3MFY2023: Capital spending −$9.8M$4.3MFY2023FY2024: Operating cash flow −$109MFY2024: Shares issued $84.0MFY2024: Capital spending −$3.1M$84.0MFY2024FY2025: Operating cash flow −$88.9MFY2025: Shares issued $202KFY2025: Asset sales $37KFY2025: Capital spending −$574K$239KFY2025
Over these 3 years operating cash flow totalled −$289M; the largest uses were operating cash flow ($289M) and capital spending ($13.5M). Cash-flow statements as filed.

Where the cash came from and went

Metagenomi Therapeutics: sources (+) and uses (−) of cash, Q2 2026Metagenomi Therapeutics: sources (+) and uses (−) of cash, Q2 2026Other investing$33.3MOperating cash flow−$19.5MCash drawn (+) / kept (−)−$13.7MCapital spending−$125KOther financing$67K
Metagenomi Therapeutics: sources (+) and uses (−) of cash, TTM to Q2 2026Metagenomi Therapeutics: sources (+) and uses (−) of cash, TTM to Q2 2026Other investing$97.2MOperating cash flow−$85.5MCash drawn (+) / kept (−)−$11.3MCapital spending−$309KOther financing−$73K

From profit to cash

Metagenomi Therapeutics: net income to operating cash flow, Q2 2026Metagenomi Therapeutics: net income to operating cash flow, Q2 2026Net income−$27.5MDepreciation & amortization$1.3MStock-based pay$2.3MPayables$319KAccrued liabilities$2.9MDeferred revenue$257KPrepaid and other assets$553KOperating cash flow−$19.5M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingShares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026−$19.5M−$125K—−$13.7M−$19.6M
Q1 2026−$21.2M−$25K—$17.2M−$21.2M
Q4 2025−$23.5M−$85K—−$8.9M−$23.6M
Q3 2025−$21.3M−$74K—−$5.9M−$21.3M
Q2 2025−$21.3M−$127K—$2.3M−$21.4M
Q1 2025−$22.8M−$288K—−$1.8M−$23.1M
Q4 2024−$26.3M−$334K—−$2.3M−$26.6M
Q3 2024−$26.6M−$1.2M−$492K$36.1M−$27.8M

Metagenomi Therapeutics: income statement and cash flow

Metagenomi Therapeutics, Q1 2026: revenue $1.2M (-70% year over year). The chart follows the revenue to costs, profit and cash.

Metagenomi Therapeutics: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.